Ligand Pharmaceuticals LGND Rylaze — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's rylaze — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's rylaze — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported rylaze — total revenues and income of $3.22M in Q1 2026.
- How has Ligand Pharmaceuticals's rylaze — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's rylaze — total revenues and income increased by 3.3% year-over-year, from $3.12M to $3.22M.
- What does rylaze — total revenues and income mean?
- This metric represents the aggregate financial inflows generated by the Rylaze product line, including both direct product sales and associated milestone or licensing payments. It serves as a key indicator of the commercial performance and market adoption of this specific therapeutic asset within the company's portfolio. Tracking this figure allows investors to assess the revenue contribution and growth trajectory of the asset independent of the broader corporate financial results.